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HM450KNeuroblastoma (NB) is one of the most frequently occurring extracranial solid tumors of childhood (Maris et al.,
2007 [1]; Brodeur, 2003 [2]). Probability of cure varies according to patient's age, extent of disease and tumor bi-
ology (Maris et al., 2007 [1]; Brodeur, 2003 [2]; Cohn et al., 2009 [3]). However, the etiology of this developmental
tumor is unknown. Recent evidence has shown that pediatric solid tumors, including NB, harbor a paucity of re-
current genetic mutations, with a signiﬁcant proportion of recurrent events converging on epigenetic mecha-
nisms (Cheung et al., 2012 [4]; Molenaar et al., 2012 [5]; Pugh et al., 2013 [6]; Sausen et al., 2013 [7].
We have analyzed the DNA methylome of neuroblastoma using high-density microarrays (Inﬁnium Human
Methylation 450k BeadChip) to deﬁne the epigenetic landscape of this pediatric tumor and its potential clinico-
pathological impact. Here, we provide the detail of methods and quality control parameters of the microarray
data used for the study. Methylation data has been deposited at NCBI Gene Expression Omnibus data repository,
accession number GSE54719; superseries record GSE54721.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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. This is an open access article under1. Direct link to deposited dataMethylation microarray data has been deposited at NCBI Gene
Expression Omnibus data repository (GEO; http://www.ncbi.nlm.
nih.gov/geo/) with accession number GSE54719 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE54719); on superseries re-
cord GSE54721 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE54721).
2. Experimental design
To deﬁne the DNA methylation landscape of neuroblastoma and its
potential clinicopathological impact. Microarray DNA methylation data
(InﬁniumHumanMethylation 450k BeadChip)were analyzed and asso-
ciated with functional/regulatory genome annotation data, transcrip-
tional proﬁles and clinico-biological parameters.
3. Material and methods
3.1. Patients and samples
Thirty-ﬁve primary neuroblastoma tumors (including 6 stage 1, 9
stage 3, 6 stage 4s and 14 stage 4) obtained at the time of diagnosisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients' clinical and biological characteristics.
Characteristics Methylation array samples (n = 35)
Age, months Median 17.90
Range 0.10–225.28
INSS, n (%) Stages 1–3 15 44.12%
Stage 4 14 41.18%
Stage 4s 6 17.65%
MYCN status, n (%) MYCN Amp 7 20.59%
MYCN non-Amp 28 82.35%
Fig. 2. Principal component analysis. AG: adrenal gland. GN: ganglioneuroma. FB: fetal
brain. NB: neuroblastoma.
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(Barcelona, Spain) were included in the study. Normal fetal brain
(n= 2) and adrenal gland (n= 2) tissues as well as ganglioneuroma
samples (n = 2) were used as reference samples. Neuroblastoma
risk assessment was deﬁned by the International Neuroblastoma
Staging System (INSS) [8]. Patients' clinical and biological character-
istics are displayed in Table 1. Tumors were evaluated by a patholo-
gist, only samples with more than 70% viable tumor cell content
were included in the study. This study was approved by the Institu-
tional Review Boards. Informed consent was obtained before collec-
tion of samples.
Genomic DNA was isolated from samples using Wizard DNA Puriﬁ-
cation Kit (Promega Biotech Ibérica, Spain), following manufactures'
protocols.Fig. 1. A: Raw β-value density plot. B: Raw β-value bean density plot. C: Scatter plot of3.2. DNA methylation microarrays
Genomic DNA bisulﬁte conversion and hybridization to Inﬁnium
Human Methylation 450k BeadChip (Illumina Inc., San Diego, CA) was
performed at the Human Genotyping Unit of the Spanish National Can-
cer Center (CEGEN-CNIO, Madrid, Spain), as described previously [9].3.3. Quality control
Microarray data was analyzed by minﬁ [10] and shinyMethyl [11]
packages available through Bioconductor [12].log median intensity of methylated (Meth) and unmethylated (Unmeth) channels.
Fig. 3. Density distributions of beta values before and after using SWAN.
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calculated as the ratio of the methylated signal intensity to the sum of
methylated and unmethylated signals. Methylation values ranged
from0, fully unmethylated, to 1, fullymethylated cytosine. Rawmethyl-
ation β-value plots were performed for all samples to identify possible
deviant samples (Fig. 1 & B).
Sample quality was assessed using the log median intensity in both
the methylated and unmethylated channels (Fig. 1C).
Principal component analysis (PCA) was performed on the 20,000
most variable autosomal probes in order to analyze associations be-
tween sample type (adrenal gland, ganglioneuroma, fetal brain or neu-
roblastoma) and methylation levels (Fig. 2).3.4. Data normalization
Microarray methylation data was normalized by missMethyl pack-
age [13] using the SWAN (subset-quantile within array normalization),
a within-array normalization method for Illumina Human Methylation
450k BeadChips (Fig. 3).Fig. 4. Data processing work-ﬂow.3.5. Filtering of microarray data
An optimized pipeline with several ﬁlters developed at the IDIBAPS
wasused to exclude technical biases, [14,15]. Cytosineswith poor detec-
tion P-values (P N 0.01) and those with sex-speciﬁc DNA methylation
(n= 6926) were removed from the initial dataset of 485,512 sites (ex-
cluding probes detecting SNPs). The remaining sites (n = 478,169)
were used for downstream analyses (Fig. 4).
3.6. Bisulﬁte pyrosequencing
DNAmethylation datawere validated by bisulﬁte pyrosequencing as
previously described [15,16] (Fig. 5).
4. Data summary
The analysis of the DNA methylome of neuroblastoma patients re-
vealed that: i) most DNA methylation changes take place outside pro-
moters, ii) not only CpGs but also non-CpG sites are targeted, iii)
methylation changes at these sites are associated with clinicopatholog-
ical features of neuroblastoma, and iv) the identiﬁed epigenetic patterns
provide new insights into the pathogenesis and clinical behavior of this
pediatric tumor. The analysis of this data has been reported in our re-
cently published study [15].
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Fig. 5. Technical DNA methylation validation. (A) Scatter plot of DNA methylation levels obtained by InﬁniumHumanMethylation 450k BeadChip (Illumina Inc., San Diego, CA) (Y-axis)
and bisulﬁte pyrosequencing (X-axis) (n = 11). A highly signiﬁcant correlation (P b 0.001, R2 = 0.978 and R2 = 0.968, respectably) between microarray and pyrosequencing data was
observed. Example of pyrograms with methylated (B) and unmethylated (C) cytosines.
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